You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Stage 1 NK

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DEFENDO Long Term Follow-up Study in Stage 1 NK Patients

Not yet recruiting
  • Neurotrophic Keratitis
  • Cenegemin in the DEFENDO Study
  • San Diego, California
  • +2 more
Dec 12, 2022

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Melanoma Trial in Columbus

Recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Dec 28, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type, Early-stage, High-Risk Cancer Trial in Beijing (Anti-PD-1 mAb,

Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Feb 23, 2022

Colon Cancer, Resected Stage Trial in Houston (Cetuximab, CB-NK-TGF-βR2-/NR3C1, Fludarabine phosphate)

Recruiting
  • Colon Cancer
  • Resected Stage
  • Houston, Texas
    M D Anderson Cancer Center
Jul 23, 2022

Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma Trial

Recruiting
  • Advanced Lung Non-Small Cell Carcinoma
  • +10 more
  • Antineoplastic Immune Cell
  • +4 more
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Aug 12, 2022

Early-stage, Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type Trial in Beijing (Anti-PD-1 mAb)

Recruiting
  • Early-stage
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Anti-PD-1 monoclonal antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Dec 7, 2021

Neurotrophic Keratitis Trial in United States (cenegermin-bkbj)

Completed
  • Neurotrophic Keratitis
  • San Diego, California
  • +4 more
Apr 11, 2022

Colon Cancer Stage I Trial in Taoyuan (Magicell-NK contains NK cells suspended in 100 mL normal saline)

Recruiting
  • Colon Cancer Stage I
  • Magicell-NK contains NK cells suspended in 100 mL normal saline
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou
Sep 28, 2022

nk/T-cell Lymphoma, Newly Diagnosed, Advanced Lymphoma Trial in Beijing (XPO1 inhibitor)

Recruiting
  • nk/T-cell Lymphoma
  • +2 more
  • XPO1 inhibitor
  • Beijing, Haidian, China
    ChinaPLAGH
Apr 18, 2023

Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8 Trial in

Not yet recruiting
  • Stage II Fallopian Tube Cancer AJCC v8
  • +33 more
  • Alpha-type-1 Polarized Dendritic Cells
  • Autologous Natural Killer Cell-like CTLs
  • Buffalo, New York
    Roswell Park Cancer Institute
Apr 1, 2022

Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)

Recruiting
  • Lymphoma
  • Radiation Therapy
  • +5 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 9, 2022

SCLC, Extensive Stage Trial in Tianjin (DLL3-CAR-NK cells)

Recruiting
  • SCLC, Extensive Stage
  • DLL3-CAR-NK cells
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Aug 18, 2022

HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma Trial in United States (procedure, drug,

Recruiting
  • HIV Infection
  • +10 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +7 more
  • La Jolla, California
  • +3 more
Dec 7, 2022

Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

Not yet recruiting
  • Myeloma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)

Not yet recruiting
  • Synovial Sarcoma
  • Fludarabine phosphate
  • +2 more
  • Houston, Texas
    MD Anderson Cancer Center
Oct 9, 2023

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

Active, not recruiting
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Anti-ICOS Monoclonal Antibody MEDI-570
  • +2 more
  • Duarte, California
  • +22 more
Jan 18, 2023

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

Melanoma Trial in New York (Pembrolizumab)

Terminated
Has Results
  • Melanoma
  • Pembrolizumab
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Oct 29, 2020

Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Guangzhou (Pegaspargase, Anti-PD-1 mAb, Definitive intensity-modulated

Not yet recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Guangzhou, Please Select, China
    Sun Yat-sen University Cancer Center
Dec 16, 2020

Solid Tumors Trial in Houston (Rimiducid, TROP2-CAR-NK Cells, Fludarabine phosphate)

Not yet recruiting
  • Solid Tumors
  • Houston, Texas
    M D Anderson Cancer Center
Sep 27, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Cytokine-Induced Memory-like Natural Killer Cells
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 22, 2023

Stage IV Ovarian Cancer, Testis Cancer, Refractory, Endometrial Cancer Recurrent Trial in Guangzhou (Claudin6 targeting CAR-NK

Recruiting
  • Stage IV Ovarian Cancer
  • +3 more
  • Claudin6 targeting CAR-NK cells
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Jun 5, 2022